"A point of care test that delivers a result in 15 minutes for a single individual cannot perform as efficiently when it's asked to deliver results for hundreds or thousands of people the workflow breaks down with too many manual handling steps in the process," said Dr.
BECKMAN COULTER LOGO SERIAL
Only Beckman Coulter's $4 SARS-CoV-2 antigen test makes large-scale, serial testing programs feasible and affordable. While point of care (POC) antigen tests have a purpose in diagnosing COVID-19, they are difficult and resource intensive to scale to address high-volume testing needs ii. Feinglass, M.D., MPH, chief medical officer for Beckman Coulter. "We are offering our solution at $4 per test because it's only with affordable and regular testing that we can address disparities and promote equity in COVID-19 testing, which is vital to address COVID-19-related health gaps and advance health equity among high-risk and underserved populations, including racial and ethnic minority groups and people living in rural areas," said Shamiram R. Our antigen assay makes the regular testing part of this equation a reality by enabling institutions and communities to implement low-cost, frequent, mass COVID-19 testing with automation, ease of handling and speed to enable scalability."īeckman Coulter's antigen test can be used for testing in high-risk settings, such as nursing homes, hospitals, universities and other group settings where repeat testing, coupled with relevant clinical information, could identify those with a SARS-CoV-2 infection to minimize transmission i. "The key to saving lives while vaccines are being put into arms is still masking, social distancing, regular testing, tracing and isolation. government's goal to expand screening because this is the right way to open up our schools, our economy and get people back to work in tandem with the massive vaccination drive that is underway," said Julie Sawyer Montgomery, president of Beckman Coulter Diagnostics. Results can be delivered in as little as 30 minutes on Beckman Coulter's immunoassay analyzers, including the DxI 800 high-throughput analyzer that can process up to 200 samples every 60 minutes. Beckman Coulter announced in December that their $4 antigen test will be available to all customers and has a confirmed 93% positive predictive agreement (PPA) and 100% negative predictive agreement (NPA).
0 kommentar(er)
